MSTN and type 1 diabetes mellitus: Our study delivers a compelling rationale for targeting the myostatin pathway as a potential adjunct therapy for T1D patients, with the purpose of providing better control of glucose homeostasis, preserving skeletal muscle mass and function, and combating the deleterious cardiometabolic consequences that accompany this disease.